Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 3:10 p.m. EDT.

Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.

About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521502258/en/

Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
[email protected]

Media Contact:
[email protected]

Source: Definium Therapeutics, Inc.

You May Also Be Interested In

• Definium Therapeutics Inc (DFTX) PT Raised to $60 at Oppenheimer
• CATL Debuts World's First Field-Validated Sodium-Ion BESS, Bringing Sodium Storage to Commercial Reality
• Minnesota or The Moon: Pulsar Helium to Present Verified Helium-3 Discovery at Quantum Tech World 2026